JP2011509279A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011509279A5 JP2011509279A5 JP2010541794A JP2010541794A JP2011509279A5 JP 2011509279 A5 JP2011509279 A5 JP 2011509279A5 JP 2010541794 A JP2010541794 A JP 2010541794A JP 2010541794 A JP2010541794 A JP 2010541794A JP 2011509279 A5 JP2011509279 A5 JP 2011509279A5
- Authority
- JP
- Japan
- Prior art keywords
- pyridin
- methyl
- pyrrolo
- phenyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 hydroxy, carboxy Chemical group 0.000 claims 229
- 150000001875 compounds Chemical class 0.000 claims 31
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 30
- 125000001475 halogen functional group Chemical group 0.000 claims 18
- 229910052799 carbon Inorganic materials 0.000 claims 14
- 125000004432 carbon atom Chemical group C* 0.000 claims 14
- 239000012453 solvate Substances 0.000 claims 14
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 13
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 11
- 125000004043 oxo group Chemical group O=* 0.000 claims 11
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 125000000623 heterocyclic group Chemical group 0.000 claims 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 125000004076 pyridyl group Chemical group 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 210000000988 bone and bone Anatomy 0.000 claims 5
- 125000004193 piperazinyl group Chemical group 0.000 claims 5
- 125000003386 piperidinyl group Chemical group 0.000 claims 5
- 150000003839 salts Chemical group 0.000 claims 5
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 4
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 3
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 3
- 150000001408 amides Chemical class 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 125000002757 morpholinyl group Chemical group 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 2
- 206010006956 Calcium deficiency Diseases 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- XONWJRHRGYJPBA-UHFFFAOYSA-N [4-[5-[6-(6-methylpyridin-2-yl)-1h-pyrrolo[2,3-b]pyridin-4-yl]pyridin-3-yl]phenyl]methanamine Chemical class CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C(C=NC=3)C=3C=CC(CN)=CC=3)C=2)=N1 XONWJRHRGYJPBA-UHFFFAOYSA-N 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 229910052791 calcium Inorganic materials 0.000 claims 2
- 239000011575 calcium Substances 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 125000006038 hexenyl group Chemical group 0.000 claims 2
- 125000001041 indolyl group Chemical group 0.000 claims 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims 2
- 125000004552 isoquinolin-4-yl group Chemical group C1=NC=C(C2=CC=CC=C12)* 0.000 claims 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 230000011164 ossification Effects 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 125000004548 quinolin-3-yl group Chemical group N1=CC(=CC2=CC=CC=C12)* 0.000 claims 2
- 230000000638 stimulation Effects 0.000 claims 2
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 claims 2
- KILIYQSGUAKAHL-QGZVFWFLSA-N (1r)-1-[4-[5-[6-(6-methylpyridin-2-yl)-1h-pyrrolo[2,3-b]pyridin-4-yl]pyridin-3-yl]phenyl]ethanamine Chemical compound C1=CC([C@H](N)C)=CC=C1C1=CN=CC(C=2C=3C=CNC=3N=C(C=2)C=2N=C(C)C=CC=2)=C1 KILIYQSGUAKAHL-QGZVFWFLSA-N 0.000 claims 1
- KILIYQSGUAKAHL-KRWDZBQOSA-N (1s)-1-[4-[5-[6-(6-methylpyridin-2-yl)-1h-pyrrolo[2,3-b]pyridin-4-yl]pyridin-3-yl]phenyl]ethanamine Chemical compound C1=CC([C@@H](N)C)=CC=C1C1=CN=CC(C=2C=3C=CNC=3N=C(C=2)C=2N=C(C)C=CC=2)=C1 KILIYQSGUAKAHL-KRWDZBQOSA-N 0.000 claims 1
- GXVMKMKFKPPUNO-SANMLTNESA-N (3s)-n,n-dimethyl-1-[[4-[5-[6-(6-methylpyridin-2-yl)-1h-pyrrolo[2,3-b]pyridin-4-yl]pyridin-3-yl]phenyl]methyl]pyrrolidin-3-amine Chemical compound C1[C@@H](N(C)C)CCN1CC1=CC=C(C=2C=C(C=NC=2)C=2C=3C=CNC=3N=C(C=2)C=2N=C(C)C=CC=2)C=C1 GXVMKMKFKPPUNO-SANMLTNESA-N 0.000 claims 1
- IUHKCKCHJIPNLZ-UHFFFAOYSA-N (4-methylpiperazin-1-yl)-[3-[5-[2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]pyridin-3-yl]phenyl]methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=CC(C=2C=C(C=NC=2)C=2C=3C=CNC=3N=C(N=2)C=2N=C(C)C=CC=2)=C1 IUHKCKCHJIPNLZ-UHFFFAOYSA-N 0.000 claims 1
- XRZAJUASIZMKJA-UHFFFAOYSA-N (4-methylpiperazin-1-yl)-[4-[5-(2-pyridin-2-yl-7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyridin-3-yl]phenyl]methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=C(C=2C=C(C=NC=2)C=2C=3C=CNC=3N=C(N=2)C=2N=CC=CC=2)C=C1 XRZAJUASIZMKJA-UHFFFAOYSA-N 0.000 claims 1
- HUDVSUWRPXEPQG-UHFFFAOYSA-N (4-methylpiperazin-1-yl)-[4-[5-[2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]pyridin-3-yl]phenyl]methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=C(C=2C=C(C=NC=2)C=2C=3C=CNC=3N=C(N=2)C=2N=C(C)C=CC=2)C=C1 HUDVSUWRPXEPQG-UHFFFAOYSA-N 0.000 claims 1
- CMCLWFVUQYCJJS-UHFFFAOYSA-N 1-[[4-[5-[6-(6-methylpyridin-2-yl)-1h-pyrrolo[2,3-b]pyridin-4-yl]pyridin-3-yl]phenyl]methyl]azetidin-3-ol Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C(C=NC=3)C=3C=CC(CN4CC(O)C4)=CC=3)C=2)=N1 CMCLWFVUQYCJJS-UHFFFAOYSA-N 0.000 claims 1
- PYHAVULIUAHIMD-UHFFFAOYSA-N 2-(6-methylpyridin-2-yl)-4-(5-phenylpyridin-3-yl)-7h-pyrrolo[2,3-d]pyrimidine Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C(C=NC=3)C=3C=CC=CC=3)N=2)=N1 PYHAVULIUAHIMD-UHFFFAOYSA-N 0.000 claims 1
- QRGPLIHBZDOWQY-UHFFFAOYSA-N 2-(6-methylpyridin-2-yl)-4-[5-(3-pyrrolidin-1-ylphenyl)pyridin-3-yl]-7h-pyrrolo[2,3-d]pyrimidine Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C(C=NC=3)C=3C=C(C=CC=3)N3CCCC3)N=2)=N1 QRGPLIHBZDOWQY-UHFFFAOYSA-N 0.000 claims 1
- AYADTPBBVYKLCC-UHFFFAOYSA-N 2-(6-methylpyridin-2-yl)-4-[5-(4-piperidin-1-ylphenyl)pyridin-3-yl]-7h-pyrrolo[2,3-d]pyrimidine Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C(C=NC=3)C=3C=CC(=CC=3)N3CCCCC3)N=2)=N1 AYADTPBBVYKLCC-UHFFFAOYSA-N 0.000 claims 1
- RFJRMCAMYRCLTG-UHFFFAOYSA-N 2-(6-methylpyridin-2-yl)-4-[5-[3-[(4-propan-2-ylpiperazin-1-yl)methyl]phenyl]pyridin-3-yl]-7h-pyrrolo[2,3-d]pyrimidine Chemical compound C1CN(C(C)C)CCN1CC1=CC=CC(C=2C=C(C=NC=2)C=2C=3C=CNC=3N=C(N=2)C=2N=C(C)C=CC=2)=C1 RFJRMCAMYRCLTG-UHFFFAOYSA-N 0.000 claims 1
- URGBVACVJQIZQQ-UHFFFAOYSA-N 2-(6-methylpyridin-2-yl)-4-[5-[4-(4-propan-2-ylpiperazin-1-yl)phenyl]pyridin-3-yl]-7h-pyrrolo[2,3-d]pyrimidine Chemical compound C1CN(C(C)C)CCN1C1=CC=C(C=2C=C(C=NC=2)C=2C=3C=CNC=3N=C(N=2)C=2N=C(C)C=CC=2)C=C1 URGBVACVJQIZQQ-UHFFFAOYSA-N 0.000 claims 1
- NDTDKLFOJIHKRT-UHFFFAOYSA-N 2-(6-methylpyridin-2-yl)-4-[5-[4-[(4-propan-2-ylpiperazin-1-yl)methyl]phenyl]pyridin-3-yl]-7h-pyrrolo[2,3-d]pyrimidine Chemical compound C1CN(C(C)C)CCN1CC1=CC=C(C=2C=C(C=NC=2)C=2C=3C=CNC=3N=C(N=2)C=2N=C(C)C=CC=2)C=C1 NDTDKLFOJIHKRT-UHFFFAOYSA-N 0.000 claims 1
- SCHKFZAJUXSFRW-UHFFFAOYSA-N 2-(6-methylpyridin-2-yl)-4-pyridin-3-yl-7h-pyrrolo[2,3-d]pyrimidine Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=NC=CC=3)N=2)=N1 SCHKFZAJUXSFRW-UHFFFAOYSA-N 0.000 claims 1
- FFPRTDNOWIKLBA-UHFFFAOYSA-N 2-[2-methyl-4-[5-[6-(6-methylpyridin-2-yl)-1h-pyrrolo[2,3-b]pyridin-4-yl]pyridin-3-yl]phenyl]propan-2-amine Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C(C=NC=3)C=3C=C(C)C(=CC=3)C(C)(C)N)C=2)=N1 FFPRTDNOWIKLBA-UHFFFAOYSA-N 0.000 claims 1
- GXPIGLBXXCBLJE-UHFFFAOYSA-N 2-[3-[5-[2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]pyridin-3-yl]phenyl]propan-2-amine Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C(C=NC=3)C=3C=C(C=CC=3)C(C)(C)N)N=2)=N1 GXPIGLBXXCBLJE-UHFFFAOYSA-N 0.000 claims 1
- KKEFAVBQMOOGBH-UHFFFAOYSA-N 2-[3-[5-[6-(6-methylpyridin-2-yl)-1h-pyrrolo[2,3-b]pyridin-4-yl]pyridin-3-yl]phenyl]acetic acid Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C(C=NC=3)C=3C=C(CC(O)=O)C=CC=3)C=2)=N1 KKEFAVBQMOOGBH-UHFFFAOYSA-N 0.000 claims 1
- FIPZROHBLDNPTC-UHFFFAOYSA-N 2-[3-methyl-4-[5-[6-(6-methylpyridin-2-yl)-1h-pyrrolo[2,3-b]pyridin-4-yl]pyridin-3-yl]phenyl]propan-2-amine Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C(C=NC=3)C=3C(=CC(=CC=3)C(C)(C)N)C)C=2)=N1 FIPZROHBLDNPTC-UHFFFAOYSA-N 0.000 claims 1
- MOBBOEPUEXEXSB-UHFFFAOYSA-N 2-[4-[5-[2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]pyridin-3-yl]phenyl]propan-2-amine Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C(C=NC=3)C=3C=CC(=CC=3)C(C)(C)N)N=2)=N1 MOBBOEPUEXEXSB-UHFFFAOYSA-N 0.000 claims 1
- OFCTUOWIXHEUBZ-UHFFFAOYSA-N 2-[4-[5-[6-(6-methylpyridin-2-yl)-1h-pyrrolo[2,3-b]pyridin-4-yl]pyridin-3-yl]phenyl]acetic acid Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C(C=NC=3)C=3C=CC(CC(O)=O)=CC=3)C=2)=N1 OFCTUOWIXHEUBZ-UHFFFAOYSA-N 0.000 claims 1
- KREWTGVYWDJLSU-UHFFFAOYSA-N 2-[[3-[5-[2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]pyridin-3-yl]phenyl]methylamino]acetic acid Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C(C=NC=3)C=3C=C(CNCC(O)=O)C=CC=3)N=2)=N1 KREWTGVYWDJLSU-UHFFFAOYSA-N 0.000 claims 1
- JROXKCZQHDIMLB-UHFFFAOYSA-N 2-[[3-[5-[2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]pyridin-3-yl]phenyl]methylamino]ethanol Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C(C=NC=3)C=3C=C(CNCCO)C=CC=3)N=2)=N1 JROXKCZQHDIMLB-UHFFFAOYSA-N 0.000 claims 1
- BXZSGRJWIZKRIB-UHFFFAOYSA-N 2-[[3-[5-[6-(6-methylpyridin-2-yl)-1h-pyrrolo[2,3-b]pyridin-4-yl]pyridin-3-yl]phenyl]methylamino]acetic acid Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C(C=NC=3)C=3C=C(CNCC(O)=O)C=CC=3)C=2)=N1 BXZSGRJWIZKRIB-UHFFFAOYSA-N 0.000 claims 1
- XMJGNVJNEQFAAH-UHFFFAOYSA-N 2-[[3-[5-[6-(6-methylpyridin-2-yl)-1h-pyrrolo[2,3-b]pyridin-4-yl]pyridin-3-yl]phenyl]methylamino]ethanol Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C(C=NC=3)C=3C=C(CNCCO)C=CC=3)C=2)=N1 XMJGNVJNEQFAAH-UHFFFAOYSA-N 0.000 claims 1
- PIMASRUZLJHZPG-UHFFFAOYSA-N 2-[[4-[5-[2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]pyridin-3-yl]phenyl]methylamino]acetic acid Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C(C=NC=3)C=3C=CC(CNCC(O)=O)=CC=3)N=2)=N1 PIMASRUZLJHZPG-UHFFFAOYSA-N 0.000 claims 1
- LTKBZHFFIZWAGM-UHFFFAOYSA-N 2-[[4-[5-[2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]pyridin-3-yl]phenyl]methylamino]ethanol Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C(C=NC=3)C=3C=CC(CNCCO)=CC=3)N=2)=N1 LTKBZHFFIZWAGM-UHFFFAOYSA-N 0.000 claims 1
- ZVMPMYPIRLXSEW-UHFFFAOYSA-N 2-[[4-[5-[6-(6-methylpyridin-2-yl)-1h-pyrrolo[2,3-b]pyridin-4-yl]pyridin-3-yl]phenyl]methylamino]ethanol Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C(C=NC=3)C=3C=CC(CNCCO)=CC=3)C=2)=N1 ZVMPMYPIRLXSEW-UHFFFAOYSA-N 0.000 claims 1
- HYDOTRODUPBFON-UHFFFAOYSA-N 2-[methyl-[[3-[5-[2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]pyridin-3-yl]phenyl]methyl]amino]ethanol Chemical compound OCCN(C)CC1=CC=CC(C=2C=C(C=NC=2)C=2C=3C=CNC=3N=C(N=2)C=2N=C(C)C=CC=2)=C1 HYDOTRODUPBFON-UHFFFAOYSA-N 0.000 claims 1
- DVOCDGDCDMUDER-UHFFFAOYSA-N 2-[methyl-[[3-[5-[6-(6-methylpyridin-2-yl)-1h-pyrrolo[2,3-b]pyridin-4-yl]pyridin-3-yl]phenyl]methyl]amino]acetic acid Chemical compound OC(=O)CN(C)CC1=CC=CC(C=2C=C(C=NC=2)C=2C=3C=CNC=3N=C(C=2)C=2N=C(C)C=CC=2)=C1 DVOCDGDCDMUDER-UHFFFAOYSA-N 0.000 claims 1
- IIXKGKWUCCUOTF-UHFFFAOYSA-N 2-[methyl-[[4-[5-[6-(6-methylpyridin-2-yl)-1h-pyrrolo[2,3-b]pyridin-4-yl]pyridin-3-yl]phenyl]methyl]amino]acetic acid Chemical compound C1=CC(CN(CC(O)=O)C)=CC=C1C1=CN=CC(C=2C=3C=CNC=3N=C(C=2)C=2N=C(C)C=CC=2)=C1 IIXKGKWUCCUOTF-UHFFFAOYSA-N 0.000 claims 1
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 1
- DUIPAMHVKRFBED-UHFFFAOYSA-N 2-pyridin-2-yl-4-pyridin-3-yl-7h-pyrrolo[2,3-d]pyrimidine Chemical compound N1=C2NC=CC2=C(C=2C=NC=CC=2)N=C1C1=CC=CC=N1 DUIPAMHVKRFBED-UHFFFAOYSA-N 0.000 claims 1
- DPASXGNZPSLEBK-UHFFFAOYSA-N 2-pyrrolidin-1-ylpyridin-3-amine Chemical compound NC1=CC=CN=C1N1CCCC1 DPASXGNZPSLEBK-UHFFFAOYSA-N 0.000 claims 1
- BAUSZGZXLWQTSV-UHFFFAOYSA-N 3-[2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]quinoline Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C4C=CC=CC4=NC=3)N=2)=N1 BAUSZGZXLWQTSV-UHFFFAOYSA-N 0.000 claims 1
- HYCCLCZIAPOJGJ-UHFFFAOYSA-N 3-[4-[5-[6-(6-methylpyridin-2-yl)-1h-pyrrolo[2,3-b]pyridin-4-yl]pyridin-3-yl]phenyl]propanoic acid Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C(C=NC=3)C=3C=CC(CCC(O)=O)=CC=3)C=2)=N1 HYCCLCZIAPOJGJ-UHFFFAOYSA-N 0.000 claims 1
- YILCKKXTQRISFS-UHFFFAOYSA-N 3-[5-[2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]pyridin-3-yl]phenol Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C(C=NC=3)C=3C=C(O)C=CC=3)N=2)=N1 YILCKKXTQRISFS-UHFFFAOYSA-N 0.000 claims 1
- REFHIBRQXDTUTD-UHFFFAOYSA-N 3-[[4-[5-[6-(6-methylpyridin-2-yl)-1h-pyrrolo[2,3-b]pyridin-4-yl]pyridin-3-yl]phenyl]methylamino]propan-1-ol Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C(C=NC=3)C=3C=CC(CNCCCO)=CC=3)C=2)=N1 REFHIBRQXDTUTD-UHFFFAOYSA-N 0.000 claims 1
- REHLMBWOMDJPSA-UHFFFAOYSA-N 3-[[4-[5-[6-(6-methylpyridin-2-yl)-1h-pyrrolo[2,3-b]pyridin-4-yl]pyridin-3-yl]phenyl]methylamino]propanoic acid Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C(C=NC=3)C=3C=CC(CNCCC(O)=O)=CC=3)C=2)=N1 REHLMBWOMDJPSA-UHFFFAOYSA-N 0.000 claims 1
- IGHNQSOWQXRDPP-UHFFFAOYSA-N 3-amino-n-[5-[2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]pyridin-3-yl]propanamide Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C(NC(=O)CCN)C=NC=3)N=2)=N1 IGHNQSOWQXRDPP-UHFFFAOYSA-N 0.000 claims 1
- DEMONGQTHRCUTI-UHFFFAOYSA-N 3-hydroxy-n-[5-[2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]pyridin-3-yl]propanamide Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C(NC(=O)CCO)C=NC=3)N=2)=N1 DEMONGQTHRCUTI-UHFFFAOYSA-N 0.000 claims 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 claims 1
- KZYCBVMCFDXQCH-UHFFFAOYSA-N 4-(4-methylpyridin-3-yl)-2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidine Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C(=CC=NC=3)C)N=2)=N1 KZYCBVMCFDXQCH-UHFFFAOYSA-N 0.000 claims 1
- MTDLDOSLLNBXFQ-UHFFFAOYSA-N 4-(5-bromopyridin-3-yl)-2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidine Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C(Br)C=NC=3)N=2)=N1 MTDLDOSLLNBXFQ-UHFFFAOYSA-N 0.000 claims 1
- IVMDEMYMESGWMX-UHFFFAOYSA-N 4-(5-bromopyridin-3-yl)-2-pyridin-2-yl-7h-pyrrolo[2,3-d]pyrimidine Chemical compound BrC1=CN=CC(C=2C=3C=CNC=3N=C(N=2)C=2N=CC=CC=2)=C1 IVMDEMYMESGWMX-UHFFFAOYSA-N 0.000 claims 1
- ZQZXLUPNUXTBAU-UHFFFAOYSA-N 4-(5-ethoxypyridin-3-yl)-6-(6-methylpyridin-2-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound CCOC1=CN=CC(C=2C=3C=CNC=3N=C(C=2)C=2N=C(C)C=CC=2)=C1 ZQZXLUPNUXTBAU-UHFFFAOYSA-N 0.000 claims 1
- LGRXCUGDUKYTII-UHFFFAOYSA-N 4-(5-methoxypyridin-3-yl)-2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidine Chemical compound COC1=CN=CC(C=2C=3C=CNC=3N=C(N=2)C=2N=C(C)C=CC=2)=C1 LGRXCUGDUKYTII-UHFFFAOYSA-N 0.000 claims 1
- DTFNHQBOMNFJLV-UHFFFAOYSA-N 4-(5-methoxypyridin-3-yl)-6-(6-methylpyridin-2-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound COC1=CN=CC(C=2C=3C=CNC=3N=C(C=2)C=2N=C(C)C=CC=2)=C1 DTFNHQBOMNFJLV-UHFFFAOYSA-N 0.000 claims 1
- XHTJVHNAENKMKQ-UHFFFAOYSA-N 4-(dimethylamino)-n-[5-[2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]pyridin-3-yl]butanamide Chemical compound CN(C)CCCC(=O)NC1=CN=CC(C=2C=3C=CNC=3N=C(N=2)C=2N=C(C)C=CC=2)=C1 XHTJVHNAENKMKQ-UHFFFAOYSA-N 0.000 claims 1
- IFQFBXRUWMZDFF-UHFFFAOYSA-N 4-[2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]isoquinoline Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C4=CC=CC=C4C=NC=3)N=2)=N1 IFQFBXRUWMZDFF-UHFFFAOYSA-N 0.000 claims 1
- GKICBBLOQKIKCQ-UHFFFAOYSA-N 4-[5-(1-methylpyrazol-4-yl)pyridin-3-yl]-2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidine Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C(C=NC=3)C3=CN(C)N=C3)N=2)=N1 GKICBBLOQKIKCQ-UHFFFAOYSA-N 0.000 claims 1
- VLEUJJOIFNNCLV-UHFFFAOYSA-N 4-[5-(2-fluorophenyl)pyridin-3-yl]-2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidine Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C(C=NC=3)C=3C(=CC=CC=3)F)N=2)=N1 VLEUJJOIFNNCLV-UHFFFAOYSA-N 0.000 claims 1
- RQTZAECQLIPPMK-UHFFFAOYSA-N 4-[5-(2-methoxyphenyl)pyridin-3-yl]-2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidine Chemical compound COC1=CC=CC=C1C1=CN=CC(C=2C=3C=CNC=3N=C(N=2)C=2N=C(C)C=CC=2)=C1 RQTZAECQLIPPMK-UHFFFAOYSA-N 0.000 claims 1
- OAOCGQNMPOSYNM-UHFFFAOYSA-N 4-[5-(2-methylphenyl)pyridin-3-yl]-2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidine Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C(C=NC=3)C=3C(=CC=CC=3)C)N=2)=N1 OAOCGQNMPOSYNM-UHFFFAOYSA-N 0.000 claims 1
- MFHMMVSFBXFYOD-UHFFFAOYSA-N 4-[5-(3-methoxyphenyl)pyridin-3-yl]-2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidine Chemical compound COC1=CC=CC(C=2C=C(C=NC=2)C=2C=3C=CNC=3N=C(N=2)C=2N=C(C)C=CC=2)=C1 MFHMMVSFBXFYOD-UHFFFAOYSA-N 0.000 claims 1
- POGPFIZKLUZTES-UHFFFAOYSA-N 4-[5-(3-methoxyphenyl)pyridin-3-yl]-6-(6-methylpyridin-2-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound COC1=CC=CC(C=2C=C(C=NC=2)C=2C=3C=CNC=3N=C(C=2)C=2N=C(C)C=CC=2)=C1 POGPFIZKLUZTES-UHFFFAOYSA-N 0.000 claims 1
- YSKLBQRYOILDLL-UHFFFAOYSA-N 4-[5-(4-fluorophenyl)pyridin-3-yl]-2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidine Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C(C=NC=3)C=3C=CC(F)=CC=3)N=2)=N1 YSKLBQRYOILDLL-UHFFFAOYSA-N 0.000 claims 1
- BDEVKFCRUCIJNB-UHFFFAOYSA-N 4-[5-(4-methoxyphenyl)pyridin-3-yl]-2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidine Chemical compound C1=CC(OC)=CC=C1C1=CN=CC(C=2C=3C=CNC=3N=C(N=2)C=2N=C(C)C=CC=2)=C1 BDEVKFCRUCIJNB-UHFFFAOYSA-N 0.000 claims 1
- CZOVBJAOBSNKDL-UHFFFAOYSA-N 4-[5-(4-methylpiperazin-1-yl)pyridin-3-yl]-2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidine Chemical compound C1CN(C)CCN1C1=CN=CC(C=2C=3C=CNC=3N=C(N=2)C=2N=C(C)C=CC=2)=C1 CZOVBJAOBSNKDL-UHFFFAOYSA-N 0.000 claims 1
- HNJGNDZXBJZQGN-UHFFFAOYSA-N 4-[5-(4-methylpiperazin-1-yl)pyridin-3-yl]-6-(6-methylpyridin-2-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1CN(C)CCN1C1=CN=CC(C=2C=3C=CNC=3N=C(C=2)C=2N=C(C)C=CC=2)=C1 HNJGNDZXBJZQGN-UHFFFAOYSA-N 0.000 claims 1
- XXUAXAUXFVRCFV-UHFFFAOYSA-N 4-[5-(cyclopenten-1-yl)pyridin-3-yl]-6-(6-methylpyridin-2-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C(C=NC=3)C=3CCCC=3)C=2)=N1 XXUAXAUXFVRCFV-UHFFFAOYSA-N 0.000 claims 1
- YJCDKEMPGFPZSD-UHFFFAOYSA-N 4-[5-[2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]pyridin-3-yl]morpholine Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C(C=NC=3)N3CCOCC3)N=2)=N1 YJCDKEMPGFPZSD-UHFFFAOYSA-N 0.000 claims 1
- GEZBFRYAHDIKJC-UHFFFAOYSA-N 4-[5-[3-(4-methylpiperazin-1-yl)prop-1-ynyl]pyridin-3-yl]-2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidine Chemical compound C1CN(C)CCN1CC#CC1=CN=CC(C=2C=3C=CNC=3N=C(N=2)C=2N=C(C)C=CC=2)=C1 GEZBFRYAHDIKJC-UHFFFAOYSA-N 0.000 claims 1
- BORHIIURRRGXGP-UHFFFAOYSA-N 4-[5-[3-(4-methylpiperazin-1-yl)prop-1-ynyl]pyridin-3-yl]-6-(6-methylpyridin-2-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1CN(C)CCN1CC#CC1=CN=CC(C=2C=3C=CNC=3N=C(C=2)C=2N=C(C)C=CC=2)=C1 BORHIIURRRGXGP-UHFFFAOYSA-N 0.000 claims 1
- GAOSSLBYVPNKLE-UHFFFAOYSA-N 4-[5-[3-[(4-methylpiperazin-1-yl)methyl]phenyl]pyridin-3-yl]-2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidine Chemical compound C1CN(C)CCN1CC1=CC=CC(C=2C=C(C=NC=2)C=2C=3C=CNC=3N=C(N=2)C=2N=C(C)C=CC=2)=C1 GAOSSLBYVPNKLE-UHFFFAOYSA-N 0.000 claims 1
- XOVGWAHCUIBCLK-UHFFFAOYSA-N 4-[5-[3-[(4-methylpiperazin-1-yl)methyl]phenyl]pyridin-3-yl]-2-pyridin-2-yl-7h-pyrrolo[2,3-d]pyrimidine Chemical compound C1CN(C)CCN1CC1=CC=CC(C=2C=C(C=NC=2)C=2C=3C=CNC=3N=C(N=2)C=2N=CC=CC=2)=C1 XOVGWAHCUIBCLK-UHFFFAOYSA-N 0.000 claims 1
- GKBMLICADBEGGJ-UHFFFAOYSA-N 4-[5-[3-[(4-methylpiperazin-1-yl)methyl]phenyl]pyridin-3-yl]-6-(6-methylpyridin-2-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1CN(C)CCN1CC1=CC=CC(C=2C=C(C=NC=2)C=2C=3C=CNC=3N=C(C=2)C=2N=C(C)C=CC=2)=C1 GKBMLICADBEGGJ-UHFFFAOYSA-N 0.000 claims 1
- XPKBWRPOJJWMJK-UHFFFAOYSA-N 4-[5-[4-(4-methylpiperazin-1-yl)phenyl]pyridin-3-yl]-2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidine Chemical compound C1CN(C)CCN1C1=CC=C(C=2C=C(C=NC=2)C=2C=3C=CNC=3N=C(N=2)C=2N=C(C)C=CC=2)C=C1 XPKBWRPOJJWMJK-UHFFFAOYSA-N 0.000 claims 1
- ANGFMEPCIJOCBD-UHFFFAOYSA-N 4-[5-[4-[(3,3-difluoropyrrolidin-1-yl)methyl]phenyl]pyridin-3-yl]-6-(6-methylpyridin-2-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C(C=NC=3)C=3C=CC(CN4CC(F)(F)CC4)=CC=3)C=2)=N1 ANGFMEPCIJOCBD-UHFFFAOYSA-N 0.000 claims 1
- QEIMUSPTWYINSB-UHFFFAOYSA-N 4-[5-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]pyridin-3-yl]-2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidine Chemical compound C1CN(C)CCN1CC1=CC=C(C=2C=C(C=NC=2)C=2C=3C=CNC=3N=C(N=2)C=2N=C(C)C=CC=2)C=C1 QEIMUSPTWYINSB-UHFFFAOYSA-N 0.000 claims 1
- BESVNGWJKCFLSN-UHFFFAOYSA-N 4-[5-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]pyridin-3-yl]-2-pyridin-2-yl-7h-pyrrolo[2,3-d]pyrimidine Chemical compound C1CN(C)CCN1CC1=CC=C(C=2C=C(C=NC=2)C=2C=3C=CNC=3N=C(N=2)C=2N=CC=CC=2)C=C1 BESVNGWJKCFLSN-UHFFFAOYSA-N 0.000 claims 1
- XROXGXMSLYKSGT-UHFFFAOYSA-N 4-[6-(6-methylpyridin-2-yl)-1h-pyrrolo[2,3-b]pyridin-4-yl]isoquinoline Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C4=CC=CC=C4C=NC=3)C=2)=N1 XROXGXMSLYKSGT-UHFFFAOYSA-N 0.000 claims 1
- SBQWXVQHXZFEKB-UHFFFAOYSA-N 4-[[3-[5-[2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]pyridin-3-yl]phenyl]methyl]morpholine Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C(C=NC=3)C=3C=C(CN4CCOCC4)C=CC=3)N=2)=N1 SBQWXVQHXZFEKB-UHFFFAOYSA-N 0.000 claims 1
- IZGPGZGPIQGNGM-UHFFFAOYSA-N 4-[[4-[5-[2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]pyridin-3-yl]phenyl]methyl]morpholine Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C(C=NC=3)C=3C=CC(CN4CCOCC4)=CC=3)N=2)=N1 IZGPGZGPIQGNGM-UHFFFAOYSA-N 0.000 claims 1
- FWOQEPSGFVHXAD-UHFFFAOYSA-N 4-[[4-[5-[6-(6-methylpyridin-2-yl)-1h-pyrrolo[2,3-b]pyridin-4-yl]pyridin-3-yl]phenyl]methyl]morpholine Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C(C=NC=3)C=3C=CC(CN4CCOCC4)=CC=3)C=2)=N1 FWOQEPSGFVHXAD-UHFFFAOYSA-N 0.000 claims 1
- SCZVRLYKQLBYSK-UHFFFAOYSA-N 4-acetamido-n-[5-[2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]pyridin-3-yl]butanamide Chemical compound CC(=O)NCCCC(=O)NC1=CN=CC(C=2C=3C=CNC=3N=C(N=2)C=2N=C(C)C=CC=2)=C1 SCZVRLYKQLBYSK-UHFFFAOYSA-N 0.000 claims 1
- JTSFIVQMXUDGAB-UHFFFAOYSA-N 4-thiomorpholin-4-ylmorpholine Chemical compound C1COCCN1N1CCSCC1 JTSFIVQMXUDGAB-UHFFFAOYSA-N 0.000 claims 1
- SZHKTQUMPIJIKS-UHFFFAOYSA-N 5-[2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]pyridin-3-ol Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C(O)C=NC=3)N=2)=N1 SZHKTQUMPIJIKS-UHFFFAOYSA-N 0.000 claims 1
- YHIOBOXWYQMRAL-UHFFFAOYSA-N 5-[2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]pyridine-3-carbonitrile Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C(C=NC=3)C#N)N=2)=N1 YHIOBOXWYQMRAL-UHFFFAOYSA-N 0.000 claims 1
- GYVCJQWEPNZWAL-UHFFFAOYSA-N 6-(6-methylpyridin-2-yl)-4-(5-methylsulfanylpyridin-3-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound CSC1=CN=CC(C=2C=3C=CNC=3N=C(C=2)C=2N=C(C)C=CC=2)=C1 GYVCJQWEPNZWAL-UHFFFAOYSA-N 0.000 claims 1
- XKDUFAPFINJXSE-UHFFFAOYSA-N 6-(6-methylpyridin-2-yl)-4-(5-propan-2-yloxypyridin-3-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound CC(C)OC1=CN=CC(C=2C=3C=CNC=3N=C(C=2)C=2N=C(C)C=CC=2)=C1 XKDUFAPFINJXSE-UHFFFAOYSA-N 0.000 claims 1
- GQCZYUJGLHVCSZ-UHFFFAOYSA-N 6-(6-methylpyridin-2-yl)-4-[5-(3-pyrrolidin-2-ylphenyl)pyridin-3-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C(C=NC=3)C=3C=C(C=CC=3)C3NCCC3)C=2)=N1 GQCZYUJGLHVCSZ-UHFFFAOYSA-N 0.000 claims 1
- PXPFTSIHJQKFGT-UHFFFAOYSA-N 6-(6-methylpyridin-2-yl)-4-[5-[4-[(4-propan-2-ylpiperazin-1-yl)methyl]phenyl]pyridin-3-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C1CN(C(C)C)CCN1CC1=CC=C(C=2C=C(C=NC=2)C=2C=3C=CNC=3N=C(C=2)C=2N=C(C)C=CC=2)C=C1 PXPFTSIHJQKFGT-UHFFFAOYSA-N 0.000 claims 1
- BDEKWMRHLQEBIO-UHFFFAOYSA-N 6-(6-methylpyridin-2-yl)-4-pyridin-3-yl-1h-pyrrolo[2,3-b]pyridine Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=NC=CC=3)C=2)=N1 BDEKWMRHLQEBIO-UHFFFAOYSA-N 0.000 claims 1
- CBXHRQJHTQHRJY-UHFFFAOYSA-N 6-[5-[2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]pyridin-3-yl]-1,2,3,4-tetrahydroisoquinoline Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C(C=NC=3)C=3C=C4CCNCC4=CC=3)N=2)=N1 CBXHRQJHTQHRJY-UHFFFAOYSA-N 0.000 claims 1
- MAQAGRJURDEYDQ-UHFFFAOYSA-N 6-methylpyridine Chemical compound CC1=C=CC=C[N]1 MAQAGRJURDEYDQ-UHFFFAOYSA-N 0.000 claims 1
- SSSPVYNDUUAUEU-UHFFFAOYSA-N 7-[5-[2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]pyridin-3-yl]-1,2,3,4-tetrahydroisoquinoline Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C(C=NC=3)C=3C=C4CNCCC4=CC=3)N=2)=N1 SSSPVYNDUUAUEU-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- OSQCJGRABJOKEJ-UHFFFAOYSA-N C(#C)C=1C=C(C=NC1)C=1C2=C(N=C(N1)C1=NC(=CC=C1)C)NC=C2.CC2=CC=CC(=N2)C=2N=C(C1=C(N2)NC=C1)C=1C=NC=C(C1)C1=NN=NN1 Chemical compound C(#C)C=1C=C(C=NC1)C=1C2=C(N=C(N1)C1=NC(=CC=C1)C)NC=C2.CC2=CC=CC(=N2)C=2N=C(C1=C(N2)NC=C1)C=1C=NC=C(C1)C1=NN=NN1 OSQCJGRABJOKEJ-UHFFFAOYSA-N 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- PMSPZNGTSXSHPV-UHFFFAOYSA-N Cc1cccc(n1)-c1ncc2cc[nH]c2n1 Chemical compound Cc1cccc(n1)-c1ncc2cc[nH]c2n1 PMSPZNGTSXSHPV-UHFFFAOYSA-N 0.000 claims 1
- 208000032544 Cicatrix Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 239000005977 Ethylene Chemical group 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000018565 Hemochromatosis Diseases 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 claims 1
- 208000002260 Keloid Diseases 0.000 claims 1
- 206010023330 Keloid scar Diseases 0.000 claims 1
- 241001024304 Mino Species 0.000 claims 1
- 208000029578 Muscle disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010051246 Photodermatosis Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- RBCOFKUKPJJTFE-UHFFFAOYSA-N [3-[5-[2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]pyridin-3-yl]phenyl]methanamine Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C(C=NC=3)C=3C=C(CN)C=CC=3)N=2)=N1 RBCOFKUKPJJTFE-UHFFFAOYSA-N 0.000 claims 1
- DEZNBMCYJAOGDC-UHFFFAOYSA-N [3-[5-[2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]pyridin-3-yl]phenyl]methanol Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C(C=NC=3)C=3C=C(CO)C=CC=3)N=2)=N1 DEZNBMCYJAOGDC-UHFFFAOYSA-N 0.000 claims 1
- JCRPMAVFYIFVBC-UHFFFAOYSA-N [3-[5-[6-(6-methylpyridin-2-yl)-1h-pyrrolo[2,3-b]pyridin-4-yl]pyridin-3-yl]phenyl]methanol Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C(C=NC=3)C=3C=C(CO)C=CC=3)C=2)=N1 JCRPMAVFYIFVBC-UHFFFAOYSA-N 0.000 claims 1
- QINHPFDZQWSTBY-UHFFFAOYSA-N [4-[5-[2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]pyridin-3-yl]phenyl]-piperazin-1-ylmethanone Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C(C=NC=3)C=3C=CC(=CC=3)C(=O)N3CCNCC3)N=2)=N1 QINHPFDZQWSTBY-UHFFFAOYSA-N 0.000 claims 1
- FIRMLABJRVEREK-UHFFFAOYSA-N [4-[5-[2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]pyridin-3-yl]phenyl]methanamine Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C(C=NC=3)C=3C=CC(CN)=CC=3)N=2)=N1 FIRMLABJRVEREK-UHFFFAOYSA-N 0.000 claims 1
- STYXKLQEDTXSMF-UHFFFAOYSA-N [4-[5-[2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]pyridin-3-yl]phenyl]methanol Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C(C=NC=3)C=3C=CC(CO)=CC=3)N=2)=N1 STYXKLQEDTXSMF-UHFFFAOYSA-N 0.000 claims 1
- YWAJAWHYUCEJME-UHFFFAOYSA-N [4-[5-[6-(6-methylpyridin-2-yl)-1h-pyrrolo[2,3-b]pyridin-4-yl]pyridin-3-yl]phenyl]methanol Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C(C=NC=3)C=3C=CC(CO)=CC=3)C=2)=N1 YWAJAWHYUCEJME-UHFFFAOYSA-N 0.000 claims 1
- QOCNILQZUNXLLW-UHFFFAOYSA-N [5-[2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]pyridin-3-yl]methanol Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C(CO)C=NC=3)N=2)=N1 QOCNILQZUNXLLW-UHFFFAOYSA-N 0.000 claims 1
- JRUPUVSUHYFWEW-UHFFFAOYSA-N [5-[6-(6-methylpyridin-2-yl)-1h-pyrrolo[2,3-b]pyridin-4-yl]pyridin-3-yl]methanol Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C(CO)C=NC=3)C=2)=N1 JRUPUVSUHYFWEW-UHFFFAOYSA-N 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 210000001117 keloid Anatomy 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- QCRHVPBKVXLXAP-UHFFFAOYSA-N methyl 2-[[3-[5-[2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]pyridin-3-yl]phenyl]methylamino]acetate Chemical compound COC(=O)CNCC1=CC=CC(C=2C=C(C=NC=2)C=2C=3C=CNC=3N=C(N=2)C=2N=C(C)C=CC=2)=C1 QCRHVPBKVXLXAP-UHFFFAOYSA-N 0.000 claims 1
- GKWLRXGCXNXMLP-UHFFFAOYSA-N methyl 2-[[3-[5-[6-(6-methylpyridin-2-yl)-1h-pyrrolo[2,3-b]pyridin-4-yl]pyridin-3-yl]phenyl]methylamino]acetate Chemical compound COC(=O)CNCC1=CC=CC(C=2C=C(C=NC=2)C=2C=3C=CNC=3N=C(C=2)C=2N=C(C)C=CC=2)=C1 GKWLRXGCXNXMLP-UHFFFAOYSA-N 0.000 claims 1
- KGADXMWLVNOSLW-UHFFFAOYSA-N methyl 2-[[4-[5-[2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]pyridin-3-yl]phenyl]methylamino]acetate Chemical compound C1=CC(CNCC(=O)OC)=CC=C1C1=CN=CC(C=2C=3C=CNC=3N=C(N=2)C=2N=C(C)C=CC=2)=C1 KGADXMWLVNOSLW-UHFFFAOYSA-N 0.000 claims 1
- RPKSEQATKOJSKZ-UHFFFAOYSA-N methyl 2-[[4-[5-[6-(6-methylpyridin-2-yl)-1h-pyrrolo[2,3-b]pyridin-4-yl]pyridin-3-yl]phenyl]methylamino]acetate Chemical compound C1=CC(CNCC(=O)OC)=CC=C1C1=CN=CC(C=2C=3C=CNC=3N=C(C=2)C=2N=C(C)C=CC=2)=C1 RPKSEQATKOJSKZ-UHFFFAOYSA-N 0.000 claims 1
- AQMWIDGKMRYBBW-UHFFFAOYSA-N methyl 2-[methyl-[[3-[5-[6-(6-methylpyridin-2-yl)-1h-pyrrolo[2,3-b]pyridin-4-yl]pyridin-3-yl]phenyl]methyl]amino]acetate Chemical compound COC(=O)CN(C)CC1=CC=CC(C=2C=C(C=NC=2)C=2C=3C=CNC=3N=C(C=2)C=2N=C(C)C=CC=2)=C1 AQMWIDGKMRYBBW-UHFFFAOYSA-N 0.000 claims 1
- BHZVBXNWIPJYFO-UHFFFAOYSA-N methyl 2-[methyl-[[4-[5-[6-(6-methylpyridin-2-yl)-1h-pyrrolo[2,3-b]pyridin-4-yl]pyridin-3-yl]phenyl]methyl]amino]acetate Chemical compound C1=CC(CN(C)CC(=O)OC)=CC=C1C1=CN=CC(C=2C=3C=CNC=3N=C(C=2)C=2N=C(C)C=CC=2)=C1 BHZVBXNWIPJYFO-UHFFFAOYSA-N 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- PQIOSYKVBBWRRI-UHFFFAOYSA-N methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 claims 1
- RRBALDQQPIMGCT-UHFFFAOYSA-N n,n-dimethyl-1-[3-[5-[2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]pyridin-3-yl]phenyl]methanamine Chemical class CN(C)CC1=CC=CC(C=2C=C(C=NC=2)C=2C=3C=CNC=3N=C(N=2)C=2N=C(C)C=CC=2)=C1 RRBALDQQPIMGCT-UHFFFAOYSA-N 0.000 claims 1
- IACXCZXVIVWNCK-UHFFFAOYSA-N n,n-dimethyl-1-[3-[5-[6-(6-methylpyridin-2-yl)-1h-pyrrolo[2,3-b]pyridin-4-yl]pyridin-3-yl]phenyl]methanamine Chemical class CN(C)CC1=CC=CC(C=2C=C(C=NC=2)C=2C=3C=CNC=3N=C(C=2)C=2N=C(C)C=CC=2)=C1 IACXCZXVIVWNCK-UHFFFAOYSA-N 0.000 claims 1
- OHQFXMINESIOFQ-UHFFFAOYSA-N n,n-dimethyl-1-[4-[5-[2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]pyridin-3-yl]phenyl]methanamine Chemical class C1=CC(CN(C)C)=CC=C1C1=CN=CC(C=2C=3C=CNC=3N=C(N=2)C=2N=C(C)C=CC=2)=C1 OHQFXMINESIOFQ-UHFFFAOYSA-N 0.000 claims 1
- XQDAMXAEJDEJGJ-UHFFFAOYSA-N n-(3-hydroxypropyl)-5-[2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]pyridine-3-carboxamide Chemical compound CC1=CC=CC(C=2N=C3NC=CC3=C(C=3C=C(C=NC=3)C(=O)NCCCO)N=2)=N1 XQDAMXAEJDEJGJ-UHFFFAOYSA-N 0.000 claims 1
- XYUHNRYKORGPMY-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]-5-[2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]pyridine-3-carboxamide Chemical compound CN(C)CCNC(=O)C1=CN=CC(C=2C=3C=CNC=3N=C(N=2)C=2N=C(C)C=CC=2)=C1 XYUHNRYKORGPMY-UHFFFAOYSA-N 0.000 claims 1
- WCFRYYCIEHUYEQ-UHFFFAOYSA-N n-[3-(4-methylpiperazin-1-yl)propyl]-5-[2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]pyridine-3-carboxamide Chemical compound C1CN(C)CCN1CCCNC(=O)C1=CN=CC(C=2C=3C=CNC=3N=C(N=2)C=2N=C(C)C=CC=2)=C1 WCFRYYCIEHUYEQ-UHFFFAOYSA-N 0.000 claims 1
- MXCNQDNBZSXROM-UHFFFAOYSA-N n-[3-(dimethylamino)propyl]-5-[2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]pyridine-3-carboxamide Chemical compound CN(C)CCCNC(=O)C1=CN=CC(C=2C=3C=CNC=3N=C(N=2)C=2N=C(C)C=CC=2)=C1 MXCNQDNBZSXROM-UHFFFAOYSA-N 0.000 claims 1
- QDKDFYLDWBTCRD-UHFFFAOYSA-N n-[5-[2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]pyridin-3-yl]propanamide Chemical compound CCC(=O)NC1=CN=CC(C=2C=3C=CNC=3N=C(N=2)C=2N=C(C)C=CC=2)=C1 QDKDFYLDWBTCRD-UHFFFAOYSA-N 0.000 claims 1
- SYJFZTDWCDUBEA-UHFFFAOYSA-N n-ethyl-5-[2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]pyridine-3-carboxamide Chemical compound CCNC(=O)C1=CN=CC(C=2C=3C=CNC=3N=C(N=2)C=2N=C(C)C=CC=2)=C1 SYJFZTDWCDUBEA-UHFFFAOYSA-N 0.000 claims 1
- GVFPEJYFEIRUDX-UHFFFAOYSA-N n-methyl-1-[3-[5-[2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]pyridin-3-yl]phenyl]methanamine Chemical class CNCC1=CC=CC(C=2C=C(C=NC=2)C=2C=3C=CNC=3N=C(N=2)C=2N=C(C)C=CC=2)=C1 GVFPEJYFEIRUDX-UHFFFAOYSA-N 0.000 claims 1
- PMMOPVPVOOUBHE-UHFFFAOYSA-N n-methyl-1-[3-[5-[6-(6-methylpyridin-2-yl)-1h-pyrrolo[2,3-b]pyridin-4-yl]pyridin-3-yl]phenyl]methanamine Chemical class CNCC1=CC=CC(C=2C=C(C=NC=2)C=2C=3C=CNC=3N=C(C=2)C=2N=C(C)C=CC=2)=C1 PMMOPVPVOOUBHE-UHFFFAOYSA-N 0.000 claims 1
- WPRJXHUPVLSTQC-UHFFFAOYSA-N n-methyl-1-[4-[5-[2-(6-methylpyridin-2-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]pyridin-3-yl]phenyl]methanamine Chemical class C1=CC(CNC)=CC=C1C1=CN=CC(C=2C=3C=CNC=3N=C(N=2)C=2N=C(C)C=CC=2)=C1 WPRJXHUPVLSTQC-UHFFFAOYSA-N 0.000 claims 1
- 230000009251 neurologic dysfunction Effects 0.000 claims 1
- 208000015015 neurological dysfunction Diseases 0.000 claims 1
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000008845 photoaging Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 238000006268 reductive amination reaction Methods 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 230000037387 scars Effects 0.000 claims 1
- 238000010561 standard procedure Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08150182 | 2008-01-11 | ||
| EP08150182.7 | 2008-01-11 | ||
| PCT/EP2009/050225 WO2009087225A2 (en) | 2008-01-11 | 2009-01-09 | Pyrrolopyrimidines and pyrrolopyridines |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011509279A JP2011509279A (ja) | 2011-03-24 |
| JP2011509279A5 true JP2011509279A5 (enExample) | 2012-02-23 |
| JP5643110B2 JP5643110B2 (ja) | 2014-12-17 |
Family
ID=39445770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010541794A Expired - Fee Related JP5643110B2 (ja) | 2008-01-11 | 2009-01-09 | ピロロピリミジン類およびピロロピリジン類 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8314112B2 (enExample) |
| EP (1) | EP2242756A2 (enExample) |
| JP (1) | JP5643110B2 (enExample) |
| KR (1) | KR20100116606A (enExample) |
| CN (1) | CN101970435B (enExample) |
| AR (1) | AR070127A1 (enExample) |
| AU (1) | AU2009203694B2 (enExample) |
| BR (1) | BRPI0907231A2 (enExample) |
| CA (1) | CA2711845A1 (enExample) |
| CL (1) | CL2009000028A1 (enExample) |
| CO (1) | CO6331340A2 (enExample) |
| CR (1) | CR11554A (enExample) |
| EA (1) | EA201001126A1 (enExample) |
| EC (1) | ECSP10010335A (enExample) |
| IL (1) | IL206819A0 (enExample) |
| MA (1) | MA31952B1 (enExample) |
| MX (1) | MX2010007605A (enExample) |
| PE (1) | PE20091306A1 (enExample) |
| TN (1) | TN2010000305A1 (enExample) |
| TW (1) | TW200934781A (enExample) |
| WO (1) | WO2009087225A2 (enExample) |
| ZA (1) | ZA201004602B (enExample) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE511509T1 (de) * | 2006-11-30 | 2011-06-15 | Genentech Inc | Azaindolylverbindungen und anwendungsverfahren |
| US8841312B2 (en) | 2007-12-19 | 2014-09-23 | Amgen Inc. | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
| JP5530422B2 (ja) | 2008-04-07 | 2014-06-25 | アムジエン・インコーポレーテツド | 細胞周期阻害薬としてのｇｅｍ−二置換およびスピロ環式アミノピリジン／ピリミジン |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| PT2300013T (pt) | 2008-05-21 | 2017-10-31 | Ariad Pharma Inc | Derivados de fósforo como inibidores de cinases |
| CA2676946A1 (en) | 2009-08-28 | 2011-02-28 | Lucie Peduto | Adam12 inhibitors and their use against inflammation-induced fibrosis |
| WO2011032050A2 (en) * | 2009-09-11 | 2011-03-17 | Trius Therapeutics, Inc. | Gyrase inhibitors |
| WO2011095196A1 (en) | 2010-02-05 | 2011-08-11 | Merck Patent Gmbh | Hetaryl-[1,8]naphthyridine derivatives |
| EA022064B1 (ru) | 2010-02-22 | 2015-10-30 | Мерк Патент Гмбх | Гетариламинонафтиридины в качестве ингибиторов атф-связывающих белков |
| BR112012021135A2 (pt) * | 2010-02-24 | 2016-06-21 | Syngenta Participations Ag | microbicidas |
| PH12012502572A1 (en) | 2010-06-30 | 2022-03-30 | Fujifilm Corp | Novel nicotinamide derivative or salt thereof |
| PE20140192A1 (es) | 2010-10-06 | 2014-02-24 | Glaxosmithkline Llc | Derivados de bencimidazol como inhibidores de cinasa pi3 |
| MY161199A (en) | 2011-03-23 | 2017-04-14 | Amgen Inc | Fused tricyclic dual inhibitors of cdk 4/6 and flt3 |
| EP2704572B1 (en) | 2011-05-04 | 2015-12-30 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
| JP5832647B2 (ja) | 2011-07-01 | 2015-12-16 | ノバルティス アーゲー | がんの治療における使用のためのｃｄｋ４／６阻害剤およびｐｉ３ｋ阻害剤を含む併用療法 |
| EP2573086A1 (en) * | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate |
| EP2573085A1 (en) | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range |
| AU2013204563B2 (en) | 2012-05-05 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
| JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
| WO2013182580A1 (en) * | 2012-06-07 | 2013-12-12 | F. Hoffmann-La Roche Ag | Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase |
| EP2867233A1 (en) * | 2012-07-03 | 2015-05-06 | Aurigene Discovery Technologies Limited | 3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS |
| US9682983B2 (en) | 2013-03-14 | 2017-06-20 | The Brigham And Women's Hospital, Inc. | BMP inhibitors and methods of use thereof |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| ES2625744T3 (es) | 2013-06-04 | 2017-07-20 | Bayer Pharma Aktiengesellschaft | Imidazo[1,2-a]piridinas sustituidas con 3-arilo y su uso |
| CA2939793A1 (en) | 2014-02-19 | 2015-08-27 | Bayer Pharma Aktiengesellschaft | 3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines |
| JP2017514793A (ja) * | 2014-03-26 | 2017-06-08 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． | Ｂｍｐ阻害用組成物及びｂｍｐ阻害方法 |
| TW201613916A (en) | 2014-06-03 | 2016-04-16 | Gilead Sciences Inc | TANK-binding kinase inhibitor compounds |
| US10513521B2 (en) | 2014-07-15 | 2019-12-24 | The Brigham And Women's Hospital, Inc. | Compositions and methods for inhibiting BMP |
| CN106715419A (zh) | 2014-09-26 | 2017-05-24 | 吉利德科学公司 | 用作tank‑结合激酶抑制剂化合物的氨基三嗪衍生物 |
| EP3227287B1 (de) | 2014-12-02 | 2019-08-07 | Bayer Pharma Aktiengesellschaft | Heteroaryl-substituierte imidazo[1,2-a]pyridine und ihre verwendung |
| WO2016172496A1 (en) | 2015-04-23 | 2016-10-27 | Constellation Pharmaceuticals, Inc. | Lsd1 inhibitors and uses thereof |
| US9840503B2 (en) | 2015-05-11 | 2017-12-12 | Incyte Corporation | Heterocyclic compounds and uses thereof |
| WO2017027717A1 (en) | 2015-08-12 | 2017-02-16 | Incyte Corporation | Bicyclic fused pyrimidine compounds as tam inhibitors |
| US10053465B2 (en) | 2015-08-26 | 2018-08-21 | Incyte Corporation | Pyrrolopyrimidine derivatives as TAM inhibitors |
| FR3041640B1 (fr) | 2015-09-30 | 2019-05-17 | Les Laboratoires Servier | NOUVEAUX DERIVES DE PYRROLO[2,3-d]PYRIMIDINE, LEUR PROCEDE DE PREPRATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT |
| AU2016370916A1 (en) | 2015-12-17 | 2018-06-07 | Gilead Sciences, Inc. | Tank-binding kinase inhibitor compounds |
| AU2016378723B2 (en) | 2015-12-22 | 2021-09-30 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
| WO2017172596A1 (en) | 2016-03-28 | 2017-10-05 | Incyte Corporation | Pyrrolotriazine compounds as tam inhibitors |
| EP3442977B1 (en) | 2016-04-15 | 2023-06-28 | Blueprint Medicines Corporation | Inhibitors of activin receptor-like kinase |
| HUE063848T2 (hu) | 2016-10-26 | 2024-02-28 | Constellation Pharmaceuticals Inc | LSD1 gátlók és gyógyászati alkalmazásaik |
| MA49458A (fr) | 2017-06-21 | 2020-04-29 | SHY Therapeutics LLC | Composés interagissant avec la superfamille ras destinés à être utilisés dans le traitement de cancers, de maladies inflammatoires, de rasopathies et de maladies fibrotiques |
| CN109384782A (zh) * | 2017-08-04 | 2019-02-26 | 厦门大学 | 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途 |
| CA3077308A1 (en) | 2017-09-27 | 2019-04-04 | Incyte Corporation | Salts of pyrrolotriazine derivatives useful as tam inhibitors |
| CN111566102B (zh) * | 2017-10-18 | 2023-09-08 | 缆图药品公司 | 作为激活素受体样激酶抑制剂的取代的吡咯并吡啶 |
| EP3728230A1 (en) * | 2017-12-22 | 2020-10-28 | Ravenna Pharmaceuticals, Inc. | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| CN111867632B (zh) * | 2018-03-23 | 2024-08-16 | 赛途公司 | 骨骼肌肥大诱导剂的alk5抑制剂 |
| PL3813800T3 (pl) | 2018-06-29 | 2025-08-18 | Incyte Corporation | Formulacje inhibitora axl/mer |
| US20200247812A1 (en) * | 2018-07-10 | 2020-08-06 | Integral Biosciences Private Limited | Heterocyclic compounds and methods of use |
| CN111018858B (zh) * | 2018-10-10 | 2022-11-18 | 复旦大学 | 杂环类衍生物及其制备方法和用途 |
| TWI827760B (zh) * | 2018-12-12 | 2024-01-01 | 加拿大商愛彼特生物製藥公司 | 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法 |
| EP3898609A1 (en) | 2018-12-19 | 2021-10-27 | Shy Therapeutics LLC | Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
| KR20200105246A (ko) * | 2019-02-28 | 2020-09-07 | 한미약품 주식회사 | 아데노신 수용체 길항제로서 신규 화합물 및 이를 포함하는 약학 조성물 |
| AU2021230385A1 (en) | 2020-03-06 | 2022-09-22 | Incyte Corporation | Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors |
| WO2021185256A1 (zh) * | 2020-03-16 | 2021-09-23 | 上海海雁医药科技有限公司 | 取代的嘧啶或吡啶胺衍生物、其组合物及医药上的用途 |
| CN113698395B (zh) * | 2020-05-22 | 2023-12-08 | 赛诺哈勃药业（成都）有限公司 | 转化生长因子受体拮抗剂、其制备方法和应用 |
| TW202210472A (zh) | 2020-06-05 | 2022-03-16 | 美商奇奈特生物製藥公司 | 纖維母細胞生長因子受體激酶之抑制劑 |
| BR112023000592A2 (pt) | 2020-07-15 | 2023-01-31 | Chiesi Farm Spa | Derivados de pirido oxazina amino como inibidores de alk5 |
| JP7686741B2 (ja) | 2020-07-15 | 2025-06-02 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | Ａｌｋ５阻害剤としてのピリダジニルアミノ誘導体 |
| EP4182322B1 (en) | 2020-07-15 | 2024-04-24 | Chiesi Farmaceutici S.p.A. | Pyrido oxazine derivatives as alk5 inhibitors |
| WO2022136221A1 (en) | 2020-12-23 | 2022-06-30 | Chiesi Farmaceutici S.P.A. | Pyrido oxazine derivatives as alk5 inhibitors |
| US20250011299A1 (en) | 2021-09-21 | 2025-01-09 | Chiesi Farmaceutici S.P.A. | Pyridazinyl amino derivatives as alk5 inhibitors |
| US20250270215A1 (en) | 2022-04-27 | 2025-08-28 | Chiesi Farmaceutici S.P.A. | Imidazole derivatives as alk5 inhibitors |
| CN118126036A (zh) * | 2022-12-01 | 2024-06-04 | 复旦大学 | 7-氮杂吲哚类化合物及其制备方法和应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ236494A3 (en) | 1992-04-03 | 1994-12-15 | Upjohn Co | Pharmaceutically active bicyclic-heterocyclic amines |
| US6686366B1 (en) * | 1998-06-02 | 2004-02-03 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
| AU4007900A (en) * | 1999-03-11 | 2000-10-16 | Neurogen Corporation | Aryl fused 2,4-disubstituted pyridines: nk3 receptor ligands |
| US6680322B2 (en) | 1999-12-02 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US7160890B2 (en) | 1999-12-02 | 2007-01-09 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
| DK1246623T3 (da) | 1999-12-02 | 2006-11-13 | Osi Pharm Inc | Forbindelser, som er specifikke for adenosin A1-, A2a- og A3-receptor og anvendelser deraf |
| US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| EA007254B1 (ru) | 2000-12-01 | 2006-08-25 | Оси Фармасьютикалз, Инк. | Соединения, специфические к аденозиновому а, аи арецептору, и их применение |
| US6673802B2 (en) | 2000-12-01 | 2004-01-06 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
| GB0100622D0 (en) | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds V111 |
| ATE446298T1 (de) | 2001-11-30 | 2009-11-15 | Osi Pharm Inc | Verbindungen, die für adenosin a1 und a3 rezeptoren spezifisch sind, und deren anwendungen |
| US20030139427A1 (en) | 2002-08-23 | 2003-07-24 | Osi Pharmaceuticals Inc. | Bicyclic pyrimidinyl derivatives and methods of use thereof |
| WO2004065392A1 (en) * | 2003-01-24 | 2004-08-05 | Smithkline Beecham Corporation | Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands |
| WO2004081009A1 (en) * | 2003-03-12 | 2004-09-23 | Millennium Pharmaceuticals, Inc. | Quinazoline derivatives as tgf-beta inhibitors |
| US20050205625A1 (en) * | 2004-03-16 | 2005-09-22 | House Arthur G | Container support device, system, and method |
| CN101119718B (zh) | 2005-02-18 | 2011-06-15 | 索尔瓦药物有限公司 | 包含nep-抑制剂，内源性内皮素产生系统抑制剂和利尿剂的药物组合物 |
| US20060205625A1 (en) | 2005-02-18 | 2006-09-14 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics |
| US20070014956A1 (en) * | 2005-07-14 | 2007-01-18 | Mccarthy Dillon P | Adhesive tape device |
| SI1962830T1 (sl) | 2005-12-23 | 2013-07-31 | Glaxosmithkline Llc | Azaindolni inhibitorji kinaz Aurora |
-
2009
- 2009-01-08 AR ARP090100050A patent/AR070127A1/es not_active Application Discontinuation
- 2009-01-09 US US12/351,438 patent/US8314112B2/en not_active Expired - Fee Related
- 2009-01-09 MX MX2010007605A patent/MX2010007605A/es active IP Right Grant
- 2009-01-09 TW TW098100815A patent/TW200934781A/zh unknown
- 2009-01-09 KR KR1020107017744A patent/KR20100116606A/ko not_active Withdrawn
- 2009-01-09 EA EA201001126A patent/EA201001126A1/ru unknown
- 2009-01-09 PE PE2009000024A patent/PE20091306A1/es not_active Application Discontinuation
- 2009-01-09 AU AU2009203694A patent/AU2009203694B2/en not_active Ceased
- 2009-01-09 WO PCT/EP2009/050225 patent/WO2009087225A2/en not_active Ceased
- 2009-01-09 CN CN200980108446.3A patent/CN101970435B/zh not_active Expired - Fee Related
- 2009-01-09 CL CL2009000028A patent/CL2009000028A1/es unknown
- 2009-01-09 EP EP20090700871 patent/EP2242756A2/en not_active Withdrawn
- 2009-01-09 CA CA2711845A patent/CA2711845A1/en not_active Abandoned
- 2009-01-09 JP JP2010541794A patent/JP5643110B2/ja not_active Expired - Fee Related
- 2009-01-09 BR BRPI0907231A patent/BRPI0907231A2/pt not_active IP Right Cessation
-
2010
- 2010-06-30 ZA ZA2010/04602A patent/ZA201004602B/en unknown
- 2010-06-30 TN TN2010000305A patent/TN2010000305A1/fr unknown
- 2010-06-30 MA MA32971A patent/MA31952B1/fr unknown
- 2010-07-02 CR CR11554A patent/CR11554A/es not_active Application Discontinuation
- 2010-07-05 IL IL206819A patent/IL206819A0/en unknown
- 2010-07-09 EC EC2010010335A patent/ECSP10010335A/es unknown
- 2010-07-12 CO CO10084491A patent/CO6331340A2/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011509279A5 (enExample) | ||
| US10669269B2 (en) | Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors | |
| JP5643110B2 (ja) | ピロロピリミジン類およびピロロピリジン類 | |
| TWI224596B (en) | Bicyclic pyridines | |
| JP2012525395A5 (enExample) | ||
| AU2004215644B2 (en) | Pyrazolopyridine derivates | |
| JP6200520B2 (ja) | 置換２−アミノピリジンプロテインキナーゼ阻害剤 | |
| RU2012136643A (ru) | [5,6]- гетероциклическое соединение | |
| JP2016513120A (ja) | 新規ピリミジン化合物 | |
| JP2018534326A5 (enExample) | ||
| JP2023021316A (ja) | ピリジンアミン－ピリドンおよびピリミジンアミン－ピリドン化合物 | |
| JP2015500332A5 (enExample) | ||
| JP2013508405A5 (enExample) | ||
| JP2012519678A5 (enExample) | ||
| EA018802B1 (ru) | Использование тиазолопиридин-2-илоксифенил- и тиазолопиразин-2-илоксифениламинов в качестве модуляторов лейкотриен а4 гидролазы | |
| CN115315422B (zh) | 酰胺类化合物及其用途 | |
| TW200413366A (en) | Compounds | |
| Liu et al. | Pyridazinone derivatives displaying highly potent and selective inhibitory activities against c-Met tyrosine kinase | |
| WO2023274390A1 (zh) | 布鲁顿酪氨酸激酶及其突变体降解剂、组合物及应用 | |
| JP7199737B2 (ja) | ピリジルピリドン化合物 | |
| JP2020531487A5 (enExample) | ||
| KR102410202B1 (ko) | Btk 억제제 화합물 | |
| HK40082804A (en) | Amide compounds and uses thereof | |
| HK40082804B (zh) | 酰胺类化合物及其用途 |